Cell line · CVCL_1650
Papers73
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 73
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Development and validation of the IFN-γ FlowCytoScreen for cytokine-based potency assessment of advanced therapy medicinal products. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. | Leukemia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chemical Markers and Bioactivity of Algerian Royal Jelly: Influence of Bee Subspecies, Geography, and Lyophilization. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway | Res Sq | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. | Cancer Immunol Immunother | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel immunotherapeutics against LGR5 to target multiple cancer types. | EMBO Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| In vitro CAR-T cell killing: validation of the potency assay. | Cancer Immunol Immunother | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. | Cell Genom | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Functional Characterization of Transforming Growth Factor-β Signaling in Dasatinib Resistance and Pre-BCR+ Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Cmpd10357 to treat B-cell acute lymphoblastic leukemia. | Exp Hematol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1650/papers